# FONGIT

> FONGIT is a VC fund in Geneva backing Software, Biotechnology and Internet. See 49 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Geneva, Switzerland
- Total investments: 49
- Last investment: Jul 2026
- Lead investor: 53%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/fongit/
- X (Twitter): https://twitter.com/Fongit1
- Website: http://www.fongit.ch/
- Facebook: https://www.facebook.com/fongit.ch

Fongit is a start-up incubator supporting high-tech ventures based in Geneva, Switzerland.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 11 | 22% |
| Biotechnology | 8 | 16% |
| Internet | 6 | 12% |
| Information Technology | 6 | 12% |
| Medical | 5 | 10% |

100 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 27 | 55% |
| Pre-Seed | 8 | 16% |
| Debt Financing | 4 | 8% |
| Angel | 3 | 6% |
| Grant | 3 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 41 | 84% |
| France | 1 | 2% |
| United Kingdom | 1 | 2% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Immitra Bio | At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommondiseases with significant unmet medical needs. | $2.8M | Pre-Seed | Jul 21, 2026 |  |
| Backbone | Backbone is the platform for instant ordering of all types of real estate visuals. The platform allows real estate teams to order, store and manage their visuals while facilitating collaboration with internal and external stakeholders. | $494.6K | Debt Financing | Jun 22, 2026 |  |
| Cria Technologies | Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers high-performance, practical solutions. | $123.8K | Pre-Seed | Jun 21, 2026 |  |
| TheraPPI Bioscience | TheraPPI Bioscience is a biotechnology based research firm for tackling and the treatment of cancer resistance and other incurable diseases. |  | Pre-Seed | Jun 01, 2026 |  |
| Clee Medical | Clee Medical believes the rapid growth of neurotech is constrained by inefficiencies in surgical tools and techniques. |  | Seed | Feb 25, 2026 |  |
| qmt | qmt provides services for watchmaking, aeronautics and defense, rail, automotive, medical, electrical engineering, and energy sectors. They design, develop and industrialize solutions that meet the requirements of their customers. Their services include project management, mechatronic systems architecture, software, mechanics, electronics, optics,and data science. | $500K | Grant | Nov 18, 2025 |  |
| Ovomind | OVOMIND proposes a new way to share and interact with video games by adding a new dimension: Emotions. Our goal is to bring back human at the centre and create a new generation of UX. | $62.5K | Grant | Nov 18, 2025 |  |
| Firefly Fusion | FireFly Fusion is pioneering the development of standard tokamaks, which open the path for fusion energy. | $50K | Grant | Apr 26, 2024 |  |
| Antion Biosciences | Antion Biosciences SA is a cell and gene engineering biotechnology company based in Geneva (Switzerland). It develops off-the-shelf therapies for the treatment of diseases with significant unmet medical needs. Antion’s proprietary technology allows for a modular and tunable approach to multiplex engineering of therapeutic cells.We have made astrategic shift to re-purpose our miCAR19 developments for autoimmune disease, building upon the recently shown in vivo proof-of-concept data with our lead product, miCAR7.Antion is one of the few players with an allogeneic solution. By leveraging its multiplex engineering technology, it has the potential to deliver a best-in-class product for B-cell-driven autoimmune disease. Significant preclinical progress has already been made, with the following value inflection point being proof-of-concept in humans. | $109.3K | Debt Financing | Apr 26, 2024 |  |
| nsave | Nsave is a fintech startup that provides a digital banking services platform that offers a secure way to save. It also offers services such as financial inclusion without account restrictions that allow customers to get global safe accounts for their money with the utmost financial security. | $4M | Seed | Mar 22, 2024 |  |

10 of 49 investments shown.

## Co-investors
- [Venture Kick](https://shizune.co/investors/profile/venturekick) — VC Fund, 4 deals together
- [Business Angels Switzerland (BAS)](https://shizune.co/investors/profile/business-angels-switzerland-bas) — VC Fund, 3 deals together
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund, 3 deals together
- [House Of Ventures](https://shizune.co/investors/profile/house-of-ventures) — VC Fund, 2 deals together
- [Kickfund](https://shizune.co/investors/profile/kickfund) — VC Fund, 2 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does FONGIT invest in?

FONGIT invests primarily in Software, Biotechnology and Internet startups, most often at Seed and Pre-Seed stage. Most of the 49 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did FONGIT last invest?

The most recent investment recorded for FONGIT closed in Jul 2026. Shizune tracks 49 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co